Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up

Insiders have been trading these 5 stocks: ((APLS)), ((OLMA)), ((XCUR)), ((IMVT)) and ((LPSN)). Here is a breakdown of their recent trades and their value.

Insider activity at Apellis Pharmaceuticals has been intense, with multiple top executives trimming their positions in a string of notable stock sales. CSO Pascal Deschatelets sold 5,928 shares for $128,993 and a further 909 shares for $17,989, while CFO Timothy Eugene Sullivan unloaded 2,892 shares for $57,232 followed by a larger sale of 10,287 shares worth $223,845. Legal leadership was also active, as GC David O. Watson sold 7,832 shares for $170,424 and another 2,475 shares for $48,980. At the very top, CEO Cedric Francois executed two major transactions, selling 8,182 shares for $161,921 and an additional 27,192 shares for a hefty $591,697. Other key officers joined in: Principal Finance Accounting executive James George Chopas sold 2,064 shares for $44,912 and 726 shares for $14,367, CTO Nur Nicholson sold 2,203 shares for $43,597 and 7,725 shares for $168,096, Chief Business & Strategy Officer Mark Jeffrey DeLong sold 3,371 shares for $73,352 and 1,334 shares for $26,399, while CMO Caroline Baumal rounded out the activity by selling 1,882 shares for $37,244 and 2,797 shares for $60,862.

Olema Pharmaceuticals saw a sharper, more focused insider move centered on a single board member. Director Cyrus Harmon executed a sizable sale of 10,000 shares of Olema Pharmaceuticals stock, generating proceeds of $268,800 from just this one transaction. While this lone sale does not match the volume of multi-executive activity seen at some peers, the clean, round figure of 10,000 shares and the nearly $270,000 value offer a clear signal that investors may watch closely for any subsequent trades or disclosures from Olema’s leadership.

At Exicure, the insider story is dominated by one major holder making two large exits that dwarf many typical insider moves. Significant shareholder HiTron Systems Inc. first sold 258,367 shares of Exicure stock for $1,162,651, then followed up with an even larger sale of 734,747 shares worth $3,306,361. Together, these transactions total nearly a million shares changing hands and more than $4.4 million in value, highlighting a substantial reduction in HiTron Systems Inc.’s stake and raising questions about long-term positioning, portfolio strategy, or shifting confidence in Exicure’s outlook.

Immunovant’s insider activity has been more modest in scale but still noteworthy given the role of the executive involved. CTO Jay S. Stout disposed of 1,977 shares of Immunovant stock in a transaction valued at $51,461. While this sale is much smaller than the multi-hundred-thousand- or multi-million-dollar moves seen elsewhere, any trade by a chief technology officer can be closely scrutinized by investors seeking to interpret internal sentiment around the company’s technological pipeline and product development trajectory.

LivePerson rounded out the recent wave of insider moves with a targeted sale from its technology leadership ranks. Chief Tech Product Officer Christopher Allen Mina sold 7,152 shares of LivePerson stock, bringing in $22,528 from the transaction. Though the dollar amount is relatively modest compared with some of the larger insider deals across the market, this sale by a key product and technology executive may be monitored by shareholders looking for patterns in insider behavior, especially when viewed alongside the company’s broader performance and strategic direction.